Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from March 26, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 24, 2026 — +22.2% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$895.00 – $920.00Entry zone — fair-value band

$914.03Published — price the day we called it

$1,060.27Target — the price the thesis aimed for

$1,182.73Peak — highest point inside the window, not a realized return

$1,117.26Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 57 days.

At window close

+22.2%

realized, from the publication price to the last close inside the window

Peak gain

+29.4%

peak, from the publication price — not a realized return

S&P 500, same window

+14%

SPY over the identical days, dividend-adjusted

Window close

$1,117.26

last close inside the window, ended June 24, 2026

Peak price

$1,182.73

peak on June 8, 2026 — not a realized return

Days to target

The thesis — published March 26, 2026

Predicted growth

+16%

over the measurement window

Target price

$1,060.27

the price the thesis aimed for

Entry zone

$895.00 – $920.00

the fair-value band we waited for

Price at publication

$914.03

published March 26, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly delivered another strong quarter and its business stayed solid during the recent pullback. The shares have slipped under the short-term trend but the fundamentals and defensive position in healthcare suggest the stock looks like it is resetting rather than failing. This gives room to recover if market swings remain high.

Primary drivers

Quarterly results showed continued strong demand for key drugs
Healthcare stocks can hold up better when markets are volatile
Recent pullback moved the stock below its short-term trend
Management tone and earnings execution reinforce confidence

How it played out

LLY: target reached in 57 days

Lyra published LLY at $914.03 with expected growth of 16% and a target of $1,060.27. The thesis expected a recovery after the pullback. It pointed to demand for key drugs, quarterly results, healthcare's defensive position during volatile markets, and management's execution.

The shares reached the target in 57 days. They peaked at $1,182.73 on June 8, a gain of 29.4% from the publication price. LLY ended the window at $1,117.26, still above the target. The thesis played out.

What happened during the window

On April 30, 2026, Lilly reported that first-quarter revenue rose 56% to $19.8 billion and raised its full-year revenue guidance. On May 26, 2026, the company announced agreements to acquire three businesses for its infectious disease portfolio.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals